NEPHROPLUS Nephrocare Health Services Q3 FY26 results (Oct–Dec 2025) and concall
NephroPlus reported robust financial performance for Q3 and 9M FY26, driven by strong revenue and profitability growth across its operations. The company saw significant expansion in adjusted EBITDA and PAT, alongside an improved ROCE. International markets, particularly the Philippines and Uzbekistan, played a crucial role in enhancing revenue per treatment and overall margins, with international contribution rising to 41% of total revenue.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 32.0%, net profit up 60.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 197 | 219 | 228 | 246 | 260 +32% |
| EBITDA | 44 | 51 | 48 | 64 | 61 +39% |
| Net profit | 20 | 25 | 24 | -9 | 32 +60% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
